secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001493152-24-043066
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa shareholders approve 150,000-share equity plan increase and up to 478,600 warrant shares
--------------------------------------------------------------------------------

- Elected Min Chul Park, Ph.D. as Class II director with 183,493 votes for, 13,425 withheld.
- Ratified Marcum LLP as independent auditor for FY2024 with 433,670 votes for.
- Approved amendment to 2022 Omnibus Equity Incentive Plan, increasing shares reserved by 150,000 to 181,795.
- Approved issuance of up to 478,600 shares upon exercise of certain warrants under Nasdaq Listing Rule 5635(d).
- Quorum of approx. 43% of outstanding shares (1,074,196 shares) was represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315224043066/0001493152-24-043066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315224043066/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer